Cognition Therapeutics Releases New Episode of "Conversations" Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
Cognition Therapeutics(CGTX) Newsfilter·2024-05-21 19:30
PURCHASE, N.Y., May 21, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, has released its eighth Conversations video podcast episode: "Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease." This episode reviews how beta amyloid (Aβ) oligomers cause synaptic dysfunction, which is correlated with cognitive decline. This conversation features a discussion of newly ...